Immuno-Oncology | Specialty

Decisions on Choosing LHRH Agonists for Treating Prostate Cancer

December 1st 2016

Use of LHRH Agonists Versus Antagonists in Prostate Cancer

December 1st 2016

Multidisciplinary Approach and Role of PSA and Testosterone Monitoring in Prostate Cancer

December 1st 2016

Intermittent versus Continuous Androgen-Deprivation Therapy in Prostate Cancer

December 1st 2016

Advanced Imaging Techniques for Prostate Cancer

December 1st 2016

Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate Cancer

December 1st 2016

IDO Inhibitors Among Immunotherapy Strategies Under Study in Glioblastoma

November 30th 2016

The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.

Dr. Rosenberg on Immunotherapeutic Advances in Bladder Cancer

November 30th 2016

Jonathan E. Rosenberg, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the emergence of immunotherapies in the field of bladder cancer, including atezolizumab (Tecentriq), nivolumab (Opdivo), and pembrolizumab (Keytruda). Rosenberg shared this at the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Checkpoint Inhibitors Changing Landscape for Advanced Solid Tumors

November 29th 2016

Immunotherapy continues to be one of the fastest-evolving fields in oncology. In recent years, numerous immunotherapies have shown good efficacy, safety, and durability across many tumor types, including some advanced solid tumors that have not seen meaningful treatment developments in decades.

Taking Steps to Manage Adverse Events Associated with Checkpoint Inhibitors

November 29th 2016

The observed adverse events that have been associated with immunotherapy, especially immunotherapy combinations, have to be properly assessed against their clearly improved efficacy in patients with otherwise dismal prognosis from stage IV cancers.

FDA Grants Priority Review to Avelumab for Merkel Cell Carcinoma

November 29th 2016

The FDA has granted a priority review to a biologics license application for avelumab as a treatment for patients with metastatic Merkel cell carcinoma.

FDA Grants Priority Review to Pembrolizumab for MSI-H Cancer

November 29th 2016

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced microsatellite instability-high cancer.

EC Approves Nivolumab for Hodgkin Lymphoma

November 23rd 2016

The European Commission has approved nivolumab for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.

"Advancing Hope": SITC Designs Innovative Educational Experience for the Management of NSCLC

November 23rd 2016

Lung cancer alone accounts for 26.5% of all cancer-related mortalities in the United States, which is more than any other malignancy. Despite increased awareness that smoking is an important risk factor for lung cancer, which has reduced the number of smokers in the U.S., nearly a quarter of a million new diagnoses are expected in 2016.

Looming Questions, Challenges Facing Physicians in Prostate Cancer

November 22nd 2016

Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.

I-SPY 2 Paves the Way for Novel HER2-Targeted Agents in Breast Cancer

November 22nd 2016

There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.

Birrer Assesses Current Challenges in Cervical Cancer

November 21st 2016

Oncologists continue to face several challenges when it comes to the prevention and treatment of cervical cancer, according to Michael Birrer, MD, PhD.

Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM

November 20th 2016

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.

Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM

November 19th 2016

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM

November 19th 2016